Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00086034 | Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma | completed | Phase 2 | 35 | Pharmacyclics LLC.INDUSTRY | 1 | May 15, 2007 | clinicaltrials |
| NCT00109356 | Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia | unknown | Phase 1 / Phase 2 | 55 | NovaceaINDUSTRY | 1 | May 7, 2007 | clinicaltrials |
| AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year |
| unknown |
| Phase 2 |
| 30 |
| Hospices Civils de LyonOTHER |
| 1 |
| Apr 27, 2007 |
| clinicaltrials |
| NCT00149136 | Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy. | unknown | Phase 2 | 30 | Hospices Civils de LyonOTHER | 1 | Apr 27, 2007 | clinicaltrials |
| NCT00143884 | Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood | terminated | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 23, 2007 | clinicaltrials |
| NCT00460447 | Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | University Hospital Carl Gustav CarusOTHER | 1 | Apr 16, 2007 | clinicaltrials |
| NCT00089596 | Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | completed | Phase 1 / Phase 2 | 10 | ViaCellINDUSTRY | 1 | Apr 12, 2007 | clinicaltrials |
| NCT00455286 | a Phase II Study in Primary Central Nervous System Lymphoma | unknown | Phase 2 | 25 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 4, 2007 | clinicaltrials |
| NCT00157274 | Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome | unknown | Phase 2 | 20 | Latin American Cooperative Onco-Haematology Group - PeruOTHER | 1 | Apr 3, 2007 | clinicaltrials |
| NCT00438581 | Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma(Zevalin) | unknown | Phase 2 | 40 | McGill UniversityOTHER | 1 | Feb 27, 2007 | clinicaltrials |
| NCT00273884 | Amonafide in Combination With Cytarabine in Secondary AML | completed | Phase 2 | 80 | Xanthus Pharmaceuticals, Inc.INDUSTRY | 2 | Feb 19, 2007 | clinicaltrials |
| NCT00327314 | Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma | unknown | Phase 2 | 100 | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Dec 28, 2006 | clinicaltrials |
| NCT00399867 | Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma. | completed | Phase 2 | 30 | Ludwig-Maximilians - University of MunichOTHER | 0 | Dec 20, 2006 | clinicaltrials |
| NCT00358020 | Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients | completed | Phase 2 | 30 | University of Turin, ItalyOTHER | 1 | Dec 4, 2006 | clinicaltrials |
| NCT00396045 | Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma | completed | Phase 1 / Phase 2 | 54 | University of Turin, ItalyOTHER | 1 | Nov 30, 2006 | clinicaltrials |
| NCT00058656 | Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients | completed | Phase 1 / Phase 2 | 18 | Xcyte TherapiesINDUSTRY | 1 | Nov 22, 2006 | clinicaltrials |
| NCT00048464 | T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant | unknown | Phase 1 / Phase 2 | 35 | Xcyte TherapiesINDUSTRY | 1 | Nov 7, 2006 | clinicaltrials |
| NCT00129948 | Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | terminated | Phase 2 | 211 | SGX Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 3, 2006 | clinicaltrials |
| NCT00329498 | L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes | suspended | Phase 2 | 25 | Samsung Medical CenterOTHER | 1 | Oct 26, 2006 | clinicaltrials |
| NCT00393107 | Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab | completed | Phase 2 | 54 | Gruppo Italiano Studio LinfomiOTHER | 1 | Oct 26, 2006 | clinicaltrials |
| NCT00261612 | Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma | unknown | Phase 2 | 16 | Medical University of ViennaOTHER | 1 | Oct 18, 2006 | clinicaltrials |
| NCT00300664 | A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. | completed | Phase 2 / Phase 3 | 150 | Royal Marsden NHS Foundation TrustOTHER | 0 | Oct 13, 2006 | clinicaltrials |
| NCT00384553 | Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma | unknown | Phase 1 / Phase 2 | 30 | University of MagdeburgOTHER | 1 | Oct 6, 2006 | clinicaltrials |
| NCT00385125 | Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL | unknown | Phase 2 | 30 | University of MagdeburgOTHER | 1 | Oct 6, 2006 | clinicaltrials |
| NCT00382694 | Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients | unknown | Phase 2 | 80 | Nordic Myeloma Study GroupOTHER | 1 | Sep 29, 2006 | clinicaltrials |
| NCT00333008 | A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. | unknown | Phase 2 | 27 | The Alvin and Lois Lapidus Cancer InstituteOTHER | 1 | Sep 26, 2006 | clinicaltrials |
| NCT00378755 | Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM | unknown | Phase 2 | 62 | Korean Multiple Myeloma Working PartyOTHER | 1 | Sep 22, 2006 | clinicaltrials |
| NCT00180895 | Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL | terminated | Phase 2 | 40 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 11, 2006 | clinicaltrials |
| NCT00138086 | Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma | completed | Phase 2 | 75 | Lymphoma Study AssociationOTHER | 3 | Sep 8, 2006 | clinicaltrials |
| NCT00067288 | Meaning-Centered Psychotherapy in Advanced Cancer | completed | Phase 2 | 118 | National Center for Complementary and Integrative Health (NCCIH)NIH | 1 | Aug 18, 2006 | clinicaltrials |
| NCT00082303 | Music Imagery for Patients Receiving Chemotherapy for Leukemia or Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 60 | National Center for Complementary and Integrative Health (NCCIH)NIH | 1 | Aug 18, 2006 | clinicaltrials |
| NCT00328237 | Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation | unknown | Phase 2 | 20 | Colorado Blood Cancer InstituteOTHER | 1 | Jun 26, 2006 | clinicaltrials |
| NCT00337506 | Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | terminated | Phase 2 | 50 | Nantes University HospitalOTHER | 1 | Jun 16, 2006 | clinicaltrials |
| NCT00096837 | A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 25 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 8, 2006 | clinicaltrials |
| NCT00044733 | Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant | completed | Phase 2 | 38 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | May 18, 2006 | clinicaltrials |
| NCT00323505 | A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma | completed | Phase 2 | — | Royal Marsden NHS Foundation TrustOTHER | 1 | May 9, 2006 | clinicaltrials |
| NCT00319865 | PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma | unknown | Phase 2 | 47 | Korean Multiple Myeloma Working PartyOTHER | 1 | Apr 27, 2006 | clinicaltrials |
| NCT00311337 | VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) | unknown | Phase 2 | 61 | University of WuerzburgOTHER | 3 | Apr 5, 2006 | clinicaltrials |
| NCT00306969 | Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma | completed | Phase 1 / Phase 2 | 18 | Boston UniversityOTHER | 1 | Mar 27, 2006 | clinicaltrials |
| NCT00299351 | A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide. | unknown | Phase 2 | 8 | Royal Marsden NHS Foundation TrustOTHER | 0 | Mar 6, 2006 | clinicaltrials |
| NCT00153582 | WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 25 | Charite University, Berlin, GermanyOTHER | 1 | Feb 22, 2006 | clinicaltrials |
| NCT00054808 | Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 40 | Genta IncorporatedINDUSTRY | 1 | Feb 8, 2006 | clinicaltrials |
| NCT00045864 | Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma. | completed | Phase 2 | — | Chiron CorporationINDUSTRY | 1 | Feb 6, 2006 | clinicaltrials |
| NCT00045877 | Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments | completed | Phase 2 / Phase 3 | — | Chiron CorporationINDUSTRY | 1 | Feb 6, 2006 | clinicaltrials |
| NCT00100737 | Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL) | terminated | Phase 2 | 300 | Chiron CorporationINDUSTRY | 1 | Feb 6, 2006 | clinicaltrials |
| NCT00035022 | Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas | completed | Phase 1 / Phase 2 | 71 | BioCryst PharmaceuticalsINDUSTRY | 1 | Jan 13, 2006 | clinicaltrials |
| NCT00219752 | Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years | completed | Phase 2 | 30 | Poitiers University HospitalOTHER | 1 | Dec 22, 2005 | clinicaltrials |
| NCT00262210 | A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers | completed | Phase 2 | 50 | National Health Research Institutes, TaiwanOTHER | 1 | Dec 6, 2005 | clinicaltrials |
| NCT00219765 | Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients | terminated | Phase 1 / Phase 2 | 30 | Poitiers University HospitalOTHER | 1 | Nov 28, 2005 | clinicaltrials |
| NCT00209833 | Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T | unknown | Phase 2 / Phase 3 | 200 | Hannover Medical SchoolOTHER | 1 | Nov 18, 2005 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2007source: clinicaltrials